ライフサイエンスコーパス: maximum tolerated dose

1 re to determine the safety, feasibility, and maximum tolerated dose.

2 s well tolerated without identification of a maximum tolerated dose.

3 ase 1 primary objective was to determine the maximum tolerated dose.

4 y, which was escalated to each participant's maximum tolerated dose.

5 ry endpoints were dose-limiting toxicity and maximum tolerated dose.

6 hase, an expansion cohort was treated at the maximum tolerated dose.

7 identify dose-limiting toxic effects and the maximum tolerated dose.

8 e used a standard 3+3 design to identify the maximum tolerated dose.

9 was started with dosing every 2 weeks at the maximum tolerated dose.

10 rmacokinetic properties and a relatively low maximum tolerated dose.

11 300 mg/day was established as the maximum tolerated dose.

12 to 400 mg in a 21-day cycle to establish the maximum tolerated dose.

13 e intravenous administration at their 10-day maximum tolerated dose.

14 vels despite receiving statin therapy at the maximum tolerated dose.

15 rformed with a 3 + 3 design to establish the maximum tolerated dose.

16 , 19 additional patients were treated at the maximum-tolerated dose.

17 g in 0.3 mug/kg per day being determined the maximum-tolerated dose.

18 disease benefit most from treatment with the maximum-tolerated dose.

19 Dose escalation to 480 mg did not identify a maximum-tolerated dose.

20 olerable when administered at the respective maximum tolerated doses.

21 Of the 18 patients given the maximum tolerated dose, 11 (61%) achieved an objective (

22 (50) = 156.8 muM), and low in vivo toxicity (maximum tolerated dose = 150 mg/kg in hamster) as compar

23 solved spontaneously or with dose reduction (maximum tolerated dose 1800 mg bid).

24 jection time (mean increase from baseline at maximum tolerated dose, 85 [SD 5] ms), the most sensitiv

25 Cyclophosphamide administered at a maximum tolerated dose activated a transient, weak innat

26 on-tumor-bearing BALB/c mice were tested for maximum tolerated dose and biodistribution.

27 e 1 primary objectives were to determine the maximum tolerated dose and dose limiting toxicities of b

28 ty of rovalpituzumab tesirine, including the maximum tolerated dose and dose-limiting toxic effects.

29 The primary endpoints were maximum tolerated dose and dose-limiting toxicity for ph

30 We aimed to establish the maximum tolerated dose and establish the recommended pha

31 The maximum tolerated dose and non-tolerated dose were not r

32 The primary objective was to determine the maximum tolerated dose and recommended dose of panobinos

33 bel, dose-escalation design to determine the maximum tolerated dose and recommended phase 2 dose (RP2

34 We aimed to define the maximum tolerated dose and recommended phase 2 dose of t

35 The primary objectives were to establish the maximum tolerated dose and recommended phase 2 dose of v

36 Maximum tolerated dose and recommended phase 2 dose were

37 limiting toxicities and determination of the maximum tolerated dose and recommended phase 2 dose.

38 nvestigator-initiated study was to determine maximum tolerated dose and safety.

39 inical studies are necessary to evaluate the maximum tolerated dose and the efficacy of (177)Lu-PP-F1

40 Primary objectives were to determine the maximum tolerated dose and the recommended dose for futu

41 The primary objective was to identify the maximum tolerated dose and the recommended phase 2 dose

42 The main goal was to define the maximum tolerated dose and to assess safety and efficacy

43 ble plexiform neurofibromas to determine the maximum tolerated dose and to evaluate plasma pharmacoki

44 hows differentiated pharmacokinetics, higher maximum tolerated doses and increased efficacy in vivo i

45 d in cohorts B, E, and H were established as maximum tolerated doses and patients were subsequently e

46 e conducted a phase I study to determine the maximum-tolerated dose and pharmacokinetics of vorinosta

47 ssess safety and tolerability, determine the maximum tolerated dose, and identify the recommended pha

48 ty and tolerability, the non-tolerated dose, maximum tolerated dose, and recommended phase 2 dose (RP

49 primary outcomes were safety, tolerability, maximum tolerated dose, and recommended phase 2 dose.

50 es were the tolerability, systemic exposure, maximum tolerated dose, and the antitumour activity of n

51 The primary endpoint in phase 1 was the maximum tolerated dose, and the primary endpoint in phas

52 Phase I and II studies show that the maximum tolerated dose, and thus the recommended dose fo

53 assess the safety profile, to determine the maximum tolerated dose, and to establish the recommended

54 article formulation increased the half-life, maximum tolerated dose, and tumor accumulation of doxoru

55 d-ISF35 viral particles (vp), with a defined maximum tolerated dose as 1 x 10(11) vp.

56 hest dose cohort tested (55 mg) exceeded the maximum tolerated dose because four of six patients expe

57 c tumor xenografts revealed that traditional maximum-tolerated dose chemotherapy, regardless of the a

58 rt 4, 2 x 10(10) vg, n=3 per cohort) and one maximum tolerated dose cohort (cohort 5, 2 x 10(10) vg,

59 Two maximum-tolerated dose combinations were identified: 200

60 ined, however, and whether escalation to the maximum tolerated dose confers clinical benefits that ou

61 alation trial was performed to determine the maximum-tolerated dose, dose-limiting toxicities, and ph

62 standard 3 + 3 design was used to determine maximum tolerated dose; dose-limiting toxicities were as

63 The 10-d maximum tolerated dose following a single i.v. injection

64 The primary endpoints were maximum tolerated dose for phase 1, and the rate of very

65 The maximum tolerated dose for sustained treatment (>28 days

66 /kg; one dose every 21 days) to identify the maximum tolerated dose for the phase 2 study.

67 During the dose-escalation phase, the maximum-tolerated dose for bendamustine was not reached;

68 ion of the route of injection as well as the maximum-tolerated dose for immunodeficient strains.

69 se-expansion part, the starting dose was the maximum tolerated dose from the dose-escalation part).

70 The primary objective (to determine the maximum tolerated dose) has been reported previously.

71 e treatment with lipid-lowering therapies at maximum tolerated doses, have an increased risk of ather

72 n three parts: dose escalation to define the maximum tolerated dose; identification of the recommende

73 phase 2 in a small number of patients at the maximum tolerated dose identified in phase 1.

74 tumumab administered once every 14 days, the maximum-tolerated dose identified in adults.

75 ndometrial carcinoma, after establishing the maximum tolerated dose in a phase 1b study.

76 agent and in combination with rituximab; the maximum tolerated dose in CLL was 1.0 mg/kg as a result

77 syndrome at 125 mg/m(2) daily x 5, thus the maximum tolerated dose in patients with myelodysplastic

78 In part B, we further investigated the maximum tolerated dose in patients with sporadic platinu

79 In phase 2, patients were enrolled at the maximum tolerated dose in the melflufen plus dexamethaso

80 re safety and tolerability, determination of maximum tolerated dose including dose-limiting toxicitie

81 avenous (IV) administration of CP-Dox at the maximum tolerated dose increases the infiltration of leu

82 best available therapy (hydroxyurea [at the maximum tolerated dose], interferon or pegylated interfe

83 horts, 10 more patients were included at the maximum tolerated dose level.

84 pletion and CD19 CAR-T cells at or below the maximum tolerated dose (</= 2 x 10(6) CAR-T cells/kg).

85 To determine the maximum tolerated dose (MTD) and dose limiting toxicity

86 Coprimary end points included maximum tolerated dose (MTD) and dose-limiting toxicity

87 escalation (3+3+3 design) study examined the maximum tolerated dose (MTD) and preliminary safety and

88 The maximum tolerated dose (MTD) and recommended phase 2 dos

89 The primary objective was to determine the maximum tolerated dose (MTD) and recommended phase 2 dos

90 In 14-day acute toxicity in rats, the maximum tolerated dose (MTD) and the no observed adverse

91 We aimed to identify the maximum tolerated dose (MTD) and the recommended phase 2

92 The aim of this study was to determine the maximum tolerated dose (MTD) and to explore the clinical

93 Dose allocation and maximum tolerated dose (MTD) estimation were guided by a

94 y objective of phase Ib was to determine the maximum tolerated dose (MTD) for lenvatinib plus pembrol

95 At the maximum tolerated dose (MTD) of 400 mug/d, the response

96 l of this phase I study was to determine the maximum tolerated dose (MTD) of alisertib with irinoteca

97 assess the safety profile and establish the maximum tolerated dose (MTD) of brentuximab vedotin in c

98 hase 1 trial in 34 patients to establish the maximum tolerated dose (MTD) of BV for SR-aGVHD treatmen

99 + 3 dose-escalation scheme to determine the maximum tolerated dose (MTD) of carfilzomib.

100 ; the primary objective was to determine the maximum tolerated dose (MTD) of isatuximab with lenalido

101 We aimed to identify the maximum tolerated dose (MTD) of lenalidomide when combin

102 Finally, the maximum tolerated dose (MTD) of NSC23925b was determined

103 Our aim was to describe the maximum tolerated dose (MTD) of oral OA in patients with

104 phase 1 dose-escalation study determined the maximum tolerated dose (MTD) of oral pomalidomide (4 dos

105 performed a phase 1/2 trial to determine the maximum tolerated dose (MTD) of pomalidomide and to expl

106 te safety and tolerability and determine the maximum tolerated dose (MTD) of single-agent, oral ixazo

107 ated in nano-formulations, which doubled the maximum tolerated dose (MTD) of Taxol.

108 1 was to assess the safety and establish the maximum tolerated dose (MTD) of the combination and phas

109 und that daily subcutaneous injection with a maximum tolerated dose (MTD) of the mGluR2/3 agonist LY3

110 The Maximum Tolerated Dose (MTD) of the particles was determ

111 was to evaluate the safety and determine the maximum tolerated dose (MTD) of the regimen.

112 rm, open-label, phase 1b study evaluated the maximum tolerated dose (MTD) of venetoclax when given wi

113 ort, patients received either Nexvax2 at the maximum tolerated dose (MTD) or placebo.

114 mmune-mediated efficacy when compared with a maximum tolerated dose (MTD) regimen in treating platinu

115 ntional chemotherapy drugs administered at a maximum tolerated dose (MTD) remains the backbone for tr

116 The maximum tolerated dose (MTD) was defined as 25 mg lenali

117 Once the maximum tolerated dose (MTD) was established, 21 patient

118 guanine-DNA alkyltransferase activity, but a maximum tolerated dose (MTD) was not reached.

119 a phase I/II study designed to determine the maximum tolerated dose (MTD), efficacy, and toxicity of

120 erlap transfusions during dose escalation to maximum tolerated dose (MTD), followed by monthly phlebo

121 When administered at maximum tolerated dose (MTD), hydroxyurea increases feta

122 first-in-human phase 1/2 study assessed the maximum tolerated dose (MTD), pharmacokinetic and pharma

123 ral Z-endoxifen to determine its toxicities, maximum tolerated dose (MTD), pharmacokinetics, and clin

124 This phase 1 study evaluated maximum tolerated dose (MTD), pharmacokinetics, pharmaco

125 were to determine the safety, tolerability, maximum tolerated dose (MTD), recommended phase 2 dose,

126 targeted agent, was carried out to determine maximum tolerated dose (MTD), safety, pharmacokinetics,

127 th factor receptors (FGFRs) to determine the maximum tolerated dose (MTD), the recommended phase II d

128 utic impact because drugs are given at their maximum tolerated dose (MTD), which compounds the toxici

129 Phase 1 established maximum tolerated dose (MTD).

130 nning hydroxyurea therapy and after reaching maximum tolerated dose (MTD).

131 eceived RVDD at 4 dose levels, including the maximum tolerated dose (MTD).

132 kinetics, we compared them on the basis of a maximum tolerated dose (MTD).

133 ts (PI-naive and PI-exposed patients) at the maximum tolerated dose (MTD).

134 We aimed to identify the maximum-tolerated dose (MTD) and dose-limiting toxicity

135 125-mg twice-per-day fed dose was deemed the maximum-tolerated dose (MTD) and RP2D.

136 evaluation of safety, pharmacokinetics, and maximum-tolerated dose (MTD) determination.

137 owder suspension was initiated at 50% of the maximum-tolerated dose (MTD) for the intact tablet.

138 y including dose-expansion cohorts after the maximum-tolerated dose (MTD) has been reached to better

139 This phase I study determined the maximum-tolerated dose (MTD) of EC145 administered as a

140 The trial objectives were to identify the maximum-tolerated dose (MTD) of first-line gemcitabine p

141 This phase Ib study sought to determine the maximum-tolerated dose (MTD) of panobinostat plus bortez

142 stituted a marked departure from the classic maximum-tolerated dose (MTD) strategy, which, given its

143 Buparlisib's maximum-tolerated dose (MTD) was 100 mg/d.

144 Dose escalation proceeded until either the maximum-tolerated dose (MTD) was achieved or, in the abs

145 nned dose was reached in all trials, but the maximum-tolerated dose (MTD) was defined in only 13 stud

146 The maximum-tolerated dose (MTD) was determined to be 25 mg

147 The maximum-tolerated dose (MTD) with dose-escalated hypofra

148 Safety, dose-limiting toxicities (DLTs), maximum-tolerated dose (MTD), and preliminary antitumor

149 ith refractory solid tumors to determine its maximum-tolerated dose (MTD), pharmacokinetics, and modu

150 This phase I study evaluated the maximum-tolerated dose (MTD), pharmacokinetics, and phar

151 We determine the maximum-tolerated dose (MTD), pharmacokinetics, safety,

152 results of a phase I trial to determine the maximum-tolerated dose (MTD), safety profile, and pharma

153 this first-in-human trial were to determine maximum-tolerated dose (MTD), safety, dose-limiting toxi

154 erformed a phase I/II study to determine the maximum-tolerated dose (MTD), safety, efficacy, and phar

155 -in-human dose-escalation study assessed the maximum-tolerated dose (MTD), safety, pharmacokinetics,

156 ase I dose-escalation study investigated the maximum-tolerated dose (MTD), safety, preliminary activi

157 del to guide dose escalation to identify the maximum-tolerated dose (MTD).

158 The maximum-tolerated doses (MTDs) were 40 mg/m(2) (schedule

159 een shown to be inferior in identifying true maximum-tolerated doses (MTDs), although the sample size

160 All patients treated at maximum-tolerated dose (n = 25) were evaluable for respo

161 The primary objective was to identify the maximum tolerated dose of (90)Y-DOTA-epratuzumab.

162 2008, and June 4, 2009, and had received the maximum tolerated dose of 15 mg lenalidomide; and 40 wer

163 At a maximum tolerated dose of 7.5 mg/kg, tumor cells in vivo

164 When dosed with the maximum tolerated dose of ALDC1, there was complete erad

165 The maximum tolerated dose of anetumab ravtansine was 6.5 mg

166 The primary objective was to determine the maximum tolerated dose of AZD1775 given in conjunction w

167 In a phase I study, the maximum tolerated dose of AZD1775 in combination with ca

168 The maximum tolerated dose of brentuximab vedotin when combi

169 iting toxicities were observed, therefore, a maximum tolerated dose of cabazitaxel of 25 mg/m(2) and

170 The primary objective was to establish the maximum tolerated dose of CPI-613 (as assessed by dose-l

171 The maximum tolerated dose of CPI-613 was 500 mg/m(2).

172 INTERPRETATION: A maximum tolerated dose of CPI-613 was established at 500

173 We aimed to establish the maximum tolerated dose of CPI-613 when used in combinati

174 The maximum tolerated dose of EC0905 in dogs was 0.25 mg/kg

175 Maximum tolerated dose of EV was not established; howeve

176 1 portion of this study was to establish the maximum tolerated dose of everolimus that could be combi

177 The maximum tolerated dose of interleukin-2 was 1x10(6) IU p

178 dose-finding methodology for estimating the maximum tolerated dose of investigational anticancer age

179 The maximum tolerated dose of ixazomib was established as 2.

180 ive of these two trials was to determine the maximum tolerated dose of lenalidomide in combination wi

181 rded no dose-limiting toxic effects, and the maximum tolerated dose of lenalidomide in combination wi

182 We aimed to determine the maximum tolerated dose of lenalidomide, an oral immunomo

183 e primary study endpoint was to identify the maximum tolerated dose of lenalidomide.

184 By contrast, the maximum tolerated dose of liposomal alendronic acid was

185 ing six patients from phase 1 treated at the maximum tolerated dose of melflufen 40 mg plus weekly de

186 refractory multiple myeloma to determine the maximum tolerated dose of melflufen and to investigate i

187 Our aim was to establish the maximum tolerated dose of no-carrier-added (NCA) (131)I-

188 The maximum tolerated dose of omecamtiv mecarbil was 0.5 mg/

189 The conjugates increased the maximum tolerated dose of paclitaxel by up to 100-fold f

190 neous weekly bortezomib, and determining the maximum tolerated dose of panobinostat in this regimen.

191 lling six escalation design to determine the maximum tolerated dose of panobinostat, and allocated pa

192 outcomes were dose-limiting toxicities, the maximum tolerated dose of ricolinostat in this combinati

193 The maximum tolerated dose of rovalpituzumab tesirine was 0.

194 Subjects self-administered the maximum tolerated dose of RW-SAIL (n = 218) or placebo (

195 The primary endpoints were the maximum tolerated dose of the combination in phase 1 and

196 In the phase 1 part, the maximum tolerated dose of the combination was not reache

197 mary end point was the identification of the maximum tolerated dose of the combination.

198 In vivo studies in mice revealed a maximum tolerated dose of TIR-199 at 25 mg/kg.

199 The maximum tolerated dose of TMZ was 100 mg/m(2).

200 The primary phase I end point was the maximum tolerated dose of TMZ.

201 3] and wound infection [grade 3]); thus, the maximum tolerated dose of TPCS2a was 1.0 mg/kg.

202 INTERPRETATION: The maximum tolerated dose of trastuzumab deruxtecan was not

203 The maximum tolerated dose of umbralisib was not reached.

204 re safety, dose-limiting toxicities, and the maximum tolerated dose of umbralisib, when given in comb

205 l (HbA1c 7.1-11.0% [54-97 mmol/mol]) despite maximum tolerated doses of metformin alone or with a sul

206 xpansion cohort at the previously determined maximum-tolerated dose of 960 mg orally twice a day.

207 , and abolished attrition produced by a near maximum-tolerated dose of PTX.

208 e event profile, dose-limiting toxicity, and maximum-tolerated dose of recombinant human IL-15 (rhIL-

209 se-limiting toxicities were observed and the maximum-tolerated dose of umbralisib was not reached.

210 treated at 960 mg twice a day, which is the maximum-tolerated dose of vemurafenib.

211 d the problem of unequal dosing by comparing maximum-tolerated doses of intravenous regimens with pro

212 thelioma received anetumab ravtansine at the maximum tolerated dose once every 3 weeks, 1.8 mg/kg onc

213 ation with chemotherapy drugs delivered with maximum tolerated dose or metronomic scheduling.

214 ability of emactuzumab, and to determine the maximum tolerated dose or optimal biological dose.

215 daily in continuous 28-day cycles until the maximum tolerated dose or recommended phase 2 dose was d

216 ts included identification of safety and the maximum tolerated dose or recommended phase 2 dosing and

217 y and tolerability, and determination of the maximum tolerated dose (or recommended phase 2 dose) of

218 ing a standard 3 + 3 design to establish the maximum tolerated dose, patients received either 1 x 10(

219 We investigated the safety, tolerability, maximum tolerated dose, pharmacokinetic and pharmacodyna

220 termine the dose-limiting toxicities (DLTs), maximum tolerated dose, pharmacokinetic profile, and res

221 Safety, maximum-tolerated dose, pharmacokinetics (PKs), pharmaco

222 Primary endpoints were maximum tolerated dose, recommended phase 2 dose, and sa

223 We aimed to assess the safety, maximum tolerated dose, recommended phase 2 dose, pharma

224 ere increased to 300 mg twice daily, with no maximum tolerated dose recorded.

225 We aimed to define feasibility, toxicity, maximum tolerated dose, response rate, and biological co

226 This phase 1/2 trial evaluated the maximum tolerated doses, safety, and efficacy of pomalid

227 points were intention-to-treat assessment of maximum-tolerated dose, safety, and dose-limiting toxici

228 administration scheme with a more classical maximum tolerated dose schedule.

229 ry objectives were safety, tolerability, and maximum tolerated dose; secondary objectives included ph

230 rocumab, when added to statin therapy at the maximum tolerated dose, significantly reduced LDL choles

231 Maximum tolerated dose studies have demonstrated safety

232 armacokinetics/pharmacodynamics studies, and maximum-tolerated-dose studies of micafungin that examin

233 They participated in a modified maximum tolerated dose study of intranasal oxytocin (Syn

234 gel containing PNC (PNC-gel) showed a lower maximum tolerated dose than PPT-containing gel (PPT-gel)

235 -Dox nanoassemblies showed a fivefold higher maximum-tolerated dose than the free drug, and moreover,

236 were receiving treatment with statins at the maximum tolerated dose (the highest dose associated with

237 A maximum tolerated dose (the highest dose associated with

238 The primary aim was to establish maximum tolerated dose (the highest infusion rate tolera

239 For the 18 patients given the maximum tolerated dose, the most common grade 3-4 non-ha

240 The primary objective was estimating the maximum tolerated dose; the secondary objectives were to

241 Although we did not identify a maximum tolerated dose, there was more gastro-intestinal

242 The primary endpoint was to estimate the maximum tolerated dose, to define the toxic effects of c

243 s-has been shown to be more efficacious than maximum tolerated dose treatment in preclinical studies,

244 assigned 1:1 to liraglutide (1.8 mg daily or maximum tolerated dose up to 1.8 mg daily) or placebo pl

245 lated during phases 1 and 2, with individual maximum tolerated doses used in phase 3.

246 signs of toxicity and a >/=3.5-fold improved maximum tolerated dose versus paclitaxel.

247 The maximum tolerated dose was 1.0 mg because of a case of e

248 The maximum tolerated dose was 10(6) CAR T cells per kg, and

249 dian number of treatment cycles given at the maximum tolerated dose was 11 (IQR 4-19).

250 The maximum tolerated dose was 2.0 mg/m(2), which 40 patient

251 The maximum tolerated dose was 25 mg per square meter (appro

252 The maximum tolerated dose was 3 mg once daily and the recom

253 follow-up of the 18 patients treated at the maximum tolerated dose was 378 days (IQR 250-602).

254 In phase 1, the established maximum tolerated dose was 40 mg of melflufen in combina

255 The maximum tolerated dose was 400 mg, and the recommended p

256 The maximum tolerated dose was defined as 1 x 10(6) CD19-CAR

257 The maximum tolerated dose was defined as the highest dose c

258 No maximum tolerated dose was defined.

259 Gilteritinib was well tolerated; the maximum tolerated dose was established as 300 mg/day whe

260 The maximum tolerated dose was established as vemurafenib 96

261 Maximum tolerated dose was established at 300 mg once we

262 The maximum tolerated dose was exceeded in the cohort receiv

263 The maximum tolerated dose was identified as lenalidomide 25

264 No maximum tolerated dose was identified in part 1.

265 No maximum tolerated dose was identified up to the maximum

266 No maximum tolerated dose was identified.

267 A maximum tolerated dose was not identified.

268 The maximum tolerated dose was not identified; the recommend

269 The maximum tolerated dose was not reached and the recommend

270 The maximum tolerated dose was not reached in either the CLL

271 The maximum tolerated dose was not reached in patients with

272 dose-limiting toxicity was observed and the maximum tolerated dose was not reached in phase 1 after

273 The maximum tolerated dose was not reached with venetoclax 6

274 The maximum tolerated dose was not reached, although full KI

275 ponatremia at the 20 mg dose), therefore the maximum tolerated dose was not reached, and 20 mg was de

276 Although the maximum tolerated dose was not reached, the RP2D for ven

277 A maximum tolerated dose was not reached.

278 The maximum tolerated dose was not reached.

279 asting 8 weeks) occurred at level 4, but the maximum tolerated dose was not reached.

280 limiting toxic effects were reported and the maximum tolerated dose was not reached.

281 ose-limiting toxicities were identified, and maximum tolerated dose was not reached.

282 able toxicity profile up to 20 mg/kg and the maximum tolerated dose was not reached.

283 occurred, at the 20 mg/kg dose, and thus the maximum tolerated dose was not reached.

284 o dose-limiting toxicities were reported and maximum tolerated dose was not reached; 500 mg daily was

285 The maximum tolerated dose was not reached; 500 mg once per

286 se-limiting toxicities were reported and the maximum tolerated dose was not reached; 800 mg twice dai

287 Therefore, the maximum tolerated dose was not reached; the recommended

288 Maximum tolerated dose was not reached; there were no do

289 Dose expansion at the maximum tolerated dose was pursued in 15 patients to con

290 No maximum tolerated dose was reached with maintenance dose

291 No maximum tolerated dose was reached.

292 d not seem to be associated with dose and no maximum tolerated dose was reached.

293 omarker studies were cited subsequently, and maximum tolerated dose was used for subsequent drug deve

294 The maximum-tolerated dose was 101 units/m(2).

295 The maximum-tolerated dose was 200 mg/day, and the dose-limi

296 The maximum-tolerated dose was 680 mg/d, and dose-limiting t

297 The maximum-tolerated dose was defined at 65 mg/m(2) using a

298 Maximum-tolerated dose was not defined.

299 A maximum-tolerated dose was not identified.

300 The maximum tolerated doses were ibrutinib 560 mg daily plus